Using HIV viral load to guide treatment-for-prevention interventions

Current Opinion in HIV and AIDS

Volumn 7, Issue 2, 2012, Pages 117-124

  Novitsky, Vladimir ^a   Essex, Max ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

antiretroviral treatment for prevention; high viremics; HIV 1 RNA load; viral linkage

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BOTSWANA; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE HOMOSEXUAL; PATIENT COMPLIANCE; PHYLOGENY; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; SURVIVAL; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 84857363953     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834fe8ff     Document Type: Review

References (85)

1. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:33-42. (Pubitemid 39490046)
2. Levy JA. The transmission of AIDS: the case of the infected cell. JAMA 1988; 259:3037-3038.
3. Kaufmann GR, Cunningham P, Kelleher AD, et al. Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J Infect Dis 1998; 178:1812-1815. (Pubitemid 28558161)
4. Kaufmann GR, Duncombe C, Zaunders J, et al. Primary HIV-1 infection: a review of clinical manifestations, immunologic and virologic changes. AIDS Patient Care STDS 1998; 12:759-767. (Pubitemid 28487710)
5. Little SJ, McLean AR, Spina CA, et al. Viral dynamics of acute HIV-1 infection. J Exp Med 1999; 190:841-850. (Pubitemid 29451629)
6. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879. (Pubitemid 37070272)
7. Schacker TW, Hughes JP, Shea T, et al. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998; 128:613-620. (Pubitemid 28169637)
8. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991; 324:961-964.
9. Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170. (Pubitemid 26001148)
10. Mellors JW, Kingsley LA, Rinaldo CRJ, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573-579.
11. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954. (Pubitemid 27255797)
12. Clark S, Saag M, Decker W, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991; 324:954-960.
13. Kassutto S, Maghsoudi K, Johnston MN, et al. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis 2006; 42:1024-1031.
14. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33-39.
15. de Wolf F, Spijkerman I, Schellekens PT, et al. AIDS prognosis based on HIV-1 RNA, CD4 T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997; 11:1799-1806. (Pubitemid 27500955)
16. Lavreys L, Baeten JM, Overbaugh J, et al. Virus load during primary human immunodeficiency virus (HIV) type 1 infection is related to the severity of acute HIV illness in Kenyan women. Clin Infect Dis 2002; 35:77-81. (Pubitemid 34666863)
17. Pilcher CD, Price MA, Hoffman IF, et al. Frequent detection of acute primary HIV infection in men in Malawi. AIDS 2004; 18:517-524. (Pubitemid 38365880)
18. Dyer JR, Kazembe P, Vernazza PL, et al. High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis 1998; 177:1742-1746. (Pubitemid 28243608)
19. Novitsky V, Woldegabriel E, Kebaabetswe L, et al. Viral load and CD4 T cell dynamics in primary HIV-1 subtype C infection. J Acquir Immune Defic Syndr 2009; 50:65-76.
20. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. JAMA 1996; 275:599-605.
21. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999; 341:394-402. (Pubitemid 29362512)
22. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335:1621-1629. (Pubitemid 26392726)
23. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999; 341:385-393. (Pubitemid 29362511)
24. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183:206-212. (Pubitemid 32066020)
25. Shapiro RL, Thior I, Gilbert PB, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 2006; 20:1281-1288. (Pubitemid 44030377)
26. Taha TE, Kumwenda NI, Hoover DR, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004; 292:202-209. (Pubitemid 38917997)
27. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000; 283:1175-1182. (Pubitemid 30126606)
28. Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of HIV-1 transmission through breastfeeding. Lancet 1992; 340:582-588.
29. Coutsoudis A, Dabis F, Fawzi W, et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004; 189:2154-2166.
30. Coutsoudis A, Pillay K, Kuhn L, et al. Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS 2001; 15:379-387. (Pubitemid 32163824)
31. Rousseau CM, Nduati RW, Richardson BA, et al. Association of levels of HIV- 1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis 2004; 190:1880-1888. (Pubitemid 39487835)
32. Richardson BA, John-Stewart GC, Hughes JP, et al. Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis 2003; 187:736-740. (Pubitemid 36286933)
33. Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 1999; 180:93-98. (Pubitemid 29293922)
34. Willumsen JF, Filteau SM, Coutsoudis A, et al. Breastmilk RNA viral load in HIV-infected South African women: effects of subclinical mastitis and infant feeding. AIDS 2003; 17:407-414. (Pubitemid 36223265)
35. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362:2282-2294. This randomized study provides convincing evidence that ARV treatment in HIVinfected mothers is highly efficient for achieving dramatic reduction of HIV transmission to infants during breastfeeding. Three regimens of ART (abacavir plus zidovudine plus lamivudine, lopinavir-ritonavir plus zidovudine plus lamivudine, and zidovudine plus lamivudine plus nevirapine) administered from pregnancy to 6-months postpartumin 730 HIV-infected mothers resulted in high rates of virologic suppression, with an overall rate of mother-to-child transmission of 1.1%.
36. Fideli US, Allen SA, Musonda R, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001; 17:901-910. (Pubitemid 32881333)
37. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929. (Pubitemid 30177052)
38. Lingappa JR,Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One 2010; 5:e12598. This study addresses the relationship between plasma HIV-1 RNA levels and HIV transmission in HIV-1 serodiscordant couples with confirmed transmission. The model developed for HIV transmission risk helps with estimation of the impact of HIV-1 transmission and evaluation of interventions aimed at averting new HIV infections.
39. Hisada M, O'Brien TR, Rosenberg PS, Goedert JJ. Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. The Multicenter Hemophilia Cohort Study. J Infect Dis 2000; 181:1475-1478. (Pubitemid 30252559)
40. Tovanabutra S, Robison V, Wongtrakul J, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002; 29:275-283. (Pubitemid 34208536)
41. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-1409. (Pubitemid 40563350)
42. Celum CL, Buchbinder SP, Donnell D, et al. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis 2001; 183:23-35. (Pubitemid 32043038)
43. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 2008; 22:2179-2185.
44. Wawer MJ, Sewankambo NK, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 1999; 353:525-535. (Pubitemid 29078422)
45. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-693.
46. Colfax GN, Buchbinder SP, Cornelisse PG, et al. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS 2002; 16:1529-1535. (Pubitemid 34804218)
47. Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol 1998; 148:88-96. (Pubitemid 28317549)
48. Jacquez JA, Koopman JS, Simon CP, Longini IM Jr. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 1994; 7:1169-1184.
49. Pilcher CD, Eron JJ Jr, Vemazza PL, et al. Sexual transmission during the incubation period of primary HIV infection. JAMA 2001; 286:1713-1714. (Pubitemid 33010256)
50. Wilson DP. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373:1077-1078; author reply 80-81.
51. Wilson DP, Law MG, Grulich AE, et al. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372:314-320. (Pubitemid 352020440)
52. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
53. De Cock KM, Gilks CF, Lo YR, Guerma T. Can antiretroviral therapy eliminate HIV transmission? Lancet 2009; 373:7-9.
54. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
55. Vernazza PL, Dyer JR, Fiscus SA, et al. HIV-1 viral load in blood, semen and saliva. AIDS 1997; 11:1058-1059. (Pubitemid 27259532)
56. Vernazza PL, Gilliam BL, Dyer J, et al. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 1997; 11:987-993. (Pubitemid 27259520)
57. Vernazza PL, Gilliam BL, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997; 11:1249-1254. (Pubitemid 27298091)
58. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000; 14:117-121. (Pubitemid 30116436)
59. Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998; 339:1803-1809. (Pubitemid 29005784)
60. Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591-601.
61. Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004; 18:81-88.
62. Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96-101.
63. Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404.
64. Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3:77ra29. This study evaluated the relationship between levels of genital HIV-1 RNA and the risk of heterosexual HIV-1 transmission in a prospective cohort of 2521 serodiscordant couples in Africa. Each 1.0 log10 increase in genital HIV-1 RNA levels was associated with about a two-fold increase in risk of HIV-1 transmission.
65. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-2098. This study assessed the effect of ART use by patients infected with HIV-1 on risk of transmission to their uninfected partners. A 92% reduction in HIV transmission was found in genetically linked cases of HIV-1 transmission. The authors conclude that low CD4 counts and high levels of HIV-1 RNA in plasma may guide the use of ART to prevent HIV-1 transmission.
66. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505. This study addressed whether early ART can reduce HIV-1 transmission in serodiscordant couples. A total of 1763 couples were randomized to receive ART either immediately or after a decline of CD4 count. A total of 39 HIV-1 transmissions occurred but only 28 were virologically linked to the infected partner. Only one transmission occurred in the early therapy group, which resulted in 96% efficacy of the early initiation of ART.
67. Venkatesh KK, Flanigan TP, Mayer KH. Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world. AIDS 2011; 25:1939-1949. This editorial review article examines the impact of wider access to ART on sexual behaviors among HIV-infected individuals in the developing world. The authors conclude that ART is associated with a significant reduction in unprotected sex following treatment initiation. However, more evidence is needed to substantiate durable decreases in sexual risk behaviors as a result of ART initiation.
68. Novitsky V, Ndung'u T, Wang R, et al. Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS 2011; 25:1515-1522. The study reports that a high proportion of individuals infected with HIV-1 subtype C in South Africa and Botswana maintain high levels of HIV-1 RNA for an extended time after acute infection. These extended high viremics have shorter time to CD4 decline, and likely contribute disproportionately to HIV-1 incidence
69. Novitsky V, Wang R, Bussmann H, et al. HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the 'test-and-treat' approach to reduce HIV transmission. PLoS One 2010; 5:e10148. This study assessed the levels and distribution of HIV-1 RNA levels in subtype C infection among 4348 drug-naïve HIV-infected individuals in Botswana, and estimated the proportion of individuals who maintain high plasma HIV-1 RNA levels for extended periods of time. The authors suggest that HIV-infected individuals with high levels of HIV-1 RNA might represent an attractive target for a modified 'test-and-treat' strategy.
70. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic; 2010. Contract No. ISBN 978-92-9173-871-7.
71. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54:535-551.
72. Altfeld M, Addo MM, Rosenberg ES, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 2003; 17:2581-2591.
73. O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet 2004; 36:565-574.
74. Murtagh MM. HIV/AIDS diagnostic landscape 2nd ed. Geneva: UNITAID Secretariat, World Health Organization; 2011. http://www.unitaid.eu/ images/marketdynamics/publications/v2-hivdiagxlandscape.pdf. [Accessed 13 December 2011] This report reviews the current landscape and cost for HIV diagnostics, and the ways in which testing is delivered, including current technology platforms. The report fo cuses on describing point-of-care CD4, HIV-1 RNA load, and infant testing platforms.
75. Wang S, Xu F, Demirci U. Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol Adv 2010; 28:770-781. The study reviews state-of-the-art technologies used for monitoring HIV-1 RNA levels in both developed and developing country settings, and discusses emerging approaches based on microfluidics and nanotechnology, which have the potential to be integrated into point-of-care HIV-1 RNA load assays.
76. Tanriverdi S, Chen L, Chen S. A rapid and automated sample-to-result HIV load test for near-patient application. J Infect Dis 2010; 201 (Suppl 1):S52-S58. This study presents evidence that the Liat HIV Quant Assay has performance equivalent to that of commercial HIV load assays and significantly reduces assay time, simplifies test operation, and provides biocontainment to allow operation in nonlaboratory settings. The Liat assay demonstrates linearity of more than 6 log10 and a limit of detection of 57 copies/ml.
77. Steinmetzer K, Seidel T, Stallmach A, Ermantraut E. HIV load testing with small samples of whole blood. J Clin Microbiol 2010; 48:2786- 2792. This study demonstrates the feasibility of small volumes of whole blood as valid samples for HIV-1 RNA load testing. Through analysis of 1094 sample pairs, the authors estimated that the probability of detecting HIV nucleic acids in 10 ml of blood was 59.3, 85.1, 91.5, and 100% when the plasma samples had an HIV-1 RNA load that was undetectable, detectable but lower than 40 copies/ml, between 40 and 4000 copies/ml, and greater than 4000 copies/ml, respectively.
78. Niemz A, Ferguson TM, Boyle DS. Point-of-care nucleic acid testing for infectious diseases. Trends Biotechnol 2011; 29:240-250.
79. LaBarre P, Hawkins KR, Gerlach J, et al. A simple, inexpensive device for nucleic acid amplification without electricity - toward instrumentfree molecular diagnostics in low-resource settings. PLoS One 2011; 6:e19738. This paper discusses the design and development of noninstrumented molecular diagnostic tests that exploit the benefits of isothermal amplification strategies. The authors identified modular instrument-free technologies for sample collection, sample preparation, amplification, heating, and detection, and suggest development of an easy-to-use, infrastructure-independent diagnostic test that can enable increased use of highly accurate molecular diagnostics at the point of care in low-resource settings.
80. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-439. This study describes a randomized, placebo-controlled trial of suppressive therapy for HSV-2 in 3408 HIV serodiscordant couples at 14 sites in Africa. Of 132 HIV-1 seroconversions that occurred after randomization, 84 were linked within couples by viral sequencing: 41 in the acyclovir group and 43 in the placebo group (P0.69). Authors conclude that daily acyclovir therapy did not reduce the risk of transmission of HIV-1, despite a reduction in plasma HIV-1 RNA of 0.25 log10 - copies/ml and a 73% reduction in the occurrence of genital ulcers due to HSV-2.
81. Campbell MS, Mullins JI, Hughes JP, et al. Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoSOne 2011; 6:e16986. This study presents methodology and results for viral linkage analysis based on HIV-1 env and gag sequences from blood plasma for 151 transmission pairs. More than one-fourth of HIV transmissions were unlinked to the enrolled partner, highlighting the importance of viral linkage analysis in the design of HIV-1 prevention trials.
82. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951-959. This study demonstrated that about 50% of new infections in men who have sex with men could be linked to other new infections in the same population in Montreal using viral genetic sequence matching.
83. Brenner BG, Roger M, Stephens D, et al. Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. J Infect Dis 2011; 204:1115-1119. Based on phylogenetic analysis and epidemiologic data, this study identified three patterns of spread of primary HIV-1 infection among men who have sex with men identified from 2001 to 2009: unique cases, small clusters (2-4 cases per cluster), and large clusters (5-31 cases per cluster). Large clusters disproportionately increased from 25.2% in 2005 to 39.1% in 2009 (P<0.001). The authors found that scalar expansion of large clusters over 11 months correlated with cluster membership size (P0.047).
84. Wester CW, Bussmann H, Koethe J, et al. Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges. HIV Ther 2009; 3:501-526.
85. Bussmann H, de la Hoz Gomez F, Roels TH, et al. Prevalence of transmitted HIV drug resistance in Botswana: lessons learned from the HIVDR-threshold survey conducted among women presenting for routine antenatal care as part of the 2007 national sentinel survey. AIDS Res Hum Retroviruses 2011; 27:365-372. This study reports results of HIV-1 drug resistance testing in 2007 in Botswana, a country with one of the longest existing national public ART programs in Africa. No significant drug resistance mutations were found. The authors conclude that after 5 years of the implementation of a public ART program in Botswana, the prevalence of transmitted drug resistance remains low, and suggest that alternative sampling strategies should be considered for the surveillance of HIV drug resistance in Botswana and similar geographic settings.